JP2024522766A5 - - Google Patents
Info
- Publication number
- JP2024522766A5 JP2024522766A5 JP2023577689A JP2023577689A JP2024522766A5 JP 2024522766 A5 JP2024522766 A5 JP 2024522766A5 JP 2023577689 A JP2023577689 A JP 2023577689A JP 2023577689 A JP2023577689 A JP 2023577689A JP 2024522766 A5 JP2024522766 A5 JP 2024522766A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- homologous
- salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110687643 | 2021-06-21 | ||
| CN202110687643.8 | 2021-06-21 | ||
| CN202110880105 | 2021-08-02 | ||
| CN202110880105.0 | 2021-08-02 | ||
| CN202111073775.8 | 2021-09-14 | ||
| CN202111073775 | 2021-09-14 | ||
| CN202111225928 | 2021-10-21 | ||
| CN202111225928.6 | 2021-10-21 | ||
| PCT/CN2022/100016 WO2022268051A1 (zh) | 2021-06-21 | 2022-06-21 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522766A JP2024522766A (ja) | 2024-06-21 |
| JP2024522766A5 true JP2024522766A5 (cg-RX-API-DMAC7.html) | 2025-07-01 |
Family
ID=84544976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577689A Pending JP2024522766A (ja) | 2021-06-21 | 2022-06-21 | 縮合四環系化合物、その調製方法及びその医薬的応用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240327434A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4361157A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522766A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240024903A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117255793B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022297474A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024646A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220929A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317587A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022268051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| CN117043167A (zh) | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| KR20250034087A (ko) * | 2022-07-09 | 2025-03-10 | 블로썸힐 테라퓨틱스, 인크. | 질병 치료를 위한 융합 고리 kras 억제제 |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| KR20250037564A (ko) * | 2022-07-29 | 2025-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Kras g12d 억제제를 포함하는 약학적 조성물 |
| CN119585278A (zh) * | 2022-08-05 | 2025-03-07 | 杭州中美华东制药有限公司 | 具有KRas G12D抑制作用的化合物 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202440594A (zh) * | 2022-12-07 | 2024-10-16 | 大陸商北京加科思新藥研發有限公司 | 稠環化合物及其用途 |
| TW202430184A (zh) * | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
| WO2024149214A1 (en) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2024159471A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024234360A1 (en) * | 2023-05-18 | 2024-11-21 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2024213979A1 (en) * | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| JP2026522894A (ja) * | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| JP2026523268A (ja) | 2023-07-13 | 2026-07-13 | 上海森▲輝▼医▲葯▼有限公司 | Kras g12d中間体の調製方法 |
| CN121843945A (zh) * | 2023-07-18 | 2026-04-10 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| CN122228262A (zh) * | 2023-11-02 | 2026-06-16 | 金橘生物科技公司 | 降解剂及其用途 |
| WO2025108443A2 (en) * | 2023-11-23 | 2025-05-30 | Beigene Switzerland Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| AU2025209726A1 (en) * | 2024-01-17 | 2026-07-09 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| CN119684315B (zh) * | 2024-01-26 | 2026-05-12 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025157261A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物晶型及其制备方法 |
| CN119490512B (zh) * | 2024-01-26 | 2026-06-16 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途 |
| CN119661555B (zh) * | 2024-01-26 | 2026-04-14 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2018206539A1 (en) | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN113874374B (zh) | 2019-05-24 | 2024-12-27 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| WO2021000885A1 (zh) | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2023025116A1 (zh) * | 2021-08-25 | 2023-03-02 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| EP4511127A1 (en) * | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
-
2022
- 2022-06-21 MX MX2023015533A patent/MX2023015533A/es unknown
- 2022-06-21 EP EP22827544.2A patent/EP4361157A4/en active Pending
- 2022-06-21 TW TW111123050A patent/TW202317587A/zh unknown
- 2022-06-21 CA CA3220929A patent/CA3220929A1/en active Pending
- 2022-06-21 BR BR112023024646A patent/BR112023024646A2/pt unknown
- 2022-06-21 AU AU2022297474A patent/AU2022297474A1/en active Pending
- 2022-06-21 JP JP2023577689A patent/JP2024522766A/ja active Pending
- 2022-06-21 WO PCT/CN2022/100016 patent/WO2022268051A1/zh not_active Ceased
- 2022-06-21 US US18/571,909 patent/US20240327434A1/en active Pending
- 2022-06-21 KR KR1020247000906A patent/KR20240024903A/ko active Pending
- 2022-06-21 CN CN202280030759.7A patent/CN117255793B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026031940A (ja) | Shp2の活性を阻害するための化合物の製造方法 | |
| JP2021519783A5 (cg-RX-API-DMAC7.html) | ||
| JP7328323B2 (ja) | SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物 | |
| JP2011527686A5 (cg-RX-API-DMAC7.html) | ||
| JP2023520333A5 (cg-RX-API-DMAC7.html) | ||
| EP3291814A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| JP2022526266A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517616A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534300A5 (cg-RX-API-DMAC7.html) | ||
| JP2025503969A5 (cg-RX-API-DMAC7.html) | ||
| JP6380777B2 (ja) | PI3K、mTOR阻害薬としての縮合キノリン化合物 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| JP2006507355A5 (cg-RX-API-DMAC7.html) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| US20240336606A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| JP2025509995A5 (cg-RX-API-DMAC7.html) | ||
| JP4823894B2 (ja) | 新規水溶性プロドラッグ | |
| JP6913955B2 (ja) | PI3K/mTOR阻害剤としての溶融キノリン化合物 | |
| KR20210146290A (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP2023554391A5 (cg-RX-API-DMAC7.html) | ||
| CN103476769B (zh) | 抗癌剂 | |
| JP2010535203A5 (cg-RX-API-DMAC7.html) | ||
| JP2025510593A (ja) | イソクロマン系化合物の結晶 | |
| TW202340142A (zh) | Gcl抑制劑 | |
| RU2023128873A (ru) | Конденсированное тетрациклическое соединение, способ его получения и его применение в медицине |